CVS Health Corporation $CVS Shares Sold by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. lessened its stake in CVS Health Corporation (NYSE:CVS) by 5.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 152,792 shares of the pharmacy operator’s stock after selling 7,972 shares during the quarter. Avantax Advisory Services Inc.’s holdings in CVS Health were worth $10,540,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Intech Investment Management LLC grew its holdings in CVS Health by 42.3% during the 2nd quarter. Intech Investment Management LLC now owns 57,611 shares of the pharmacy operator’s stock worth $3,974,000 after acquiring an additional 17,130 shares in the last quarter. MJP Associates Inc. ADV acquired a new position in shares of CVS Health during the second quarter worth $203,000. Cetera Investment Advisers increased its holdings in CVS Health by 4.7% in the second quarter. Cetera Investment Advisers now owns 361,284 shares of the pharmacy operator’s stock valued at $24,921,000 after buying an additional 16,321 shares during the last quarter. New England Capital Financial Advisors LLC raised its stake in CVS Health by 48.0% in the second quarter. New England Capital Financial Advisors LLC now owns 971 shares of the pharmacy operator’s stock valued at $67,000 after buying an additional 315 shares in the last quarter. Finally, OmniStar Financial Group Inc. purchased a new stake in CVS Health during the 2nd quarter worth about $223,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.22% of the company’s stock.

CVS Health Stock Up 0.6%

CVS stock opened at $78.24 on Tuesday. The company has a market cap of $99.32 billion, a price-to-earnings ratio of 205.89, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The company has a fifty day moving average price of $77.86 and a 200 day moving average price of $70.02. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.62. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. During the same period in the previous year, the business posted $1.09 earnings per share. CVS Health’s quarterly revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio is currently 700.00%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CVS shares. UBS Group increased their price objective on CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a report on Friday, October 24th. Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and increased their price target for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. Piper Sandler raised their price objective on shares of CVS Health from $81.00 to $99.00 in a report on Friday, October 31st. Jefferies Financial Group upped their target price on shares of CVS Health from $92.00 to $98.00 in a report on Thursday, October 30th. Finally, Royal Bank Of Canada lifted their price target on shares of CVS Health from $81.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $89.41.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.